An endoscopic topical therapy for the treatment of Helicobacter pylori infection

Kimura, Ken; Ido, Kenichi; Kihira, Ken; Saifuku, Koji; Taniguchi, Yushi; Sato, Katsuaki; Takimoto, T; Yoshida, Yukio

doi:10.1016/0016-5085(95)23189-7

Cited by 21 publications

(35 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Those of us who advocate taking the drugs with meals must also caution patients to ignore that warning. While the use of intravenously administered drugs has not been studied systematically, at a minimum it has not shown any advantage and 1 hour topical therapy in which the duodenum was blocked with a balloon proved effective in most patients 105 . Often the relation of drug administration and meals is not reported.…”

Section: Issues Ripe For Systematic Studymentioning

confidence: 99%

How to Effectively Use Bismuth Quadruple Therapy

Graham

Lee

2015

Gastroenterology Clinics of North America

132

174

View full text Add to dashboard Cite

Bismuth triple therapy was the first truly effective Helicobacter pylori eradication therapy. The addition of a proton pump inhibitor largely overcame the problem of metronidazole resistance. Resistance to its being the primary first line therapy have centered on convenience (the large number of tablets required) and side effects causing difficulties with patient adherence. Understanding why the regimen is less successful in some regions remains unexplained in part because of the lack of studies including susceptibility testing. A number of modifications have been proposed such as twice-a-day therapy which addresses both major criticism but the studies with susceptibility testing required to prove its effectiveness in high metronidazole resistance areas are lacking. Most publications lack the data required to understand why they were successful or failed (e.g., detailed resistance and adherence data) and are therefore of little value. We discuss and provide recommendations regarding variations including substitution of doxycycline, amoxicillin, and twice a day therapy. We describe what is known and unknown and provide suggestions regarding what is needed to rationally and effectively use bismuth quadruple therapy. Its primary use is when penicillin cannot be used or when clarithromycin and metronidazole resistance is common. Durations of therapy less than 14 days are not recommended.

show abstract

Section: Issues Ripe For Systematic Studymentioning

confidence: 99%

How to Effectively Use Bismuth Quadruple Therapy

Graham

Lee

2015

Gastroenterology Clinics of North America

132

174

View full text Add to dashboard Cite

show abstract

“…Kimura et al. used pronase as part of their topical therapy for the treatment of H. pylori infection [21], but little is known about the additive effect of pronase during eradication therapy.…”

mentioning

confidence: 99%

Additive Effect of Pronase on the Efficacy of Eradication Therapy Against Helicobacter pylori

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Helicobacter pylori is recognised as a primary cause of active chronic gastritis and is reported to be associated with peptic ulcer disease [1,2], low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue and gastric adenocarcinoma [3,4]. Like the cell envelope of all other gram-negative bacteria, that of H. pylori contains lipopolysaccharide (LPS).…”

Section: Introductionmentioning

confidence: 99%

Non-standard biological activities of lipopolysaccharide from Helicobacter pylori

Matsuyama¹,

Kirikae

et al. 2001

Journal of Medical Microbiology

View full text Add to dashboard Cite

As assessed by the lipopolysaccharide (LPS)-speci®c chromogenic Limulus amoebocyte lysate (LAL) assay, Helicobacter pylori LPS extracted by the phenol-water procedure showed full potency to coagulate LAL, as did LPS from Salmonella minnesota and Escherichia coli. However, pretreatment of H. pylori LPS with polymyxin B, which easily destroys the endotoxic activity of enterobacterial LPS/lipid A, had little effect on the LAL coagulation activity, although the same treatment of E. coli LPS markedly diminished its activity. The H. pylori LPS induced very weak production of nitric oxide (NO) or tumour necrosis factor (TNF) by murine macrophages and TNF by human peripheral whole blood in vitro in comparison with S. minnesota LPS. These ®ndings indicate that H. pylori LPS has the unique endotoxic characteristic of retaining full LAL coagulation activity with polymyxin B resistance, despite losing its endotoxic potencies such as the ability to induce NO and TNF production.

show abstract

An endoscopic topical therapy for the treatment of Helicobacter pylori infection

Cited by 21 publications

References 0 publications

How to Effectively Use Bismuth Quadruple Therapy

How to Effectively Use Bismuth Quadruple Therapy

Additive Effect of Pronase on the Efficacy of Eradication Therapy Against Helicobacter pylori

Non-standard biological activities of lipopolysaccharide from Helicobacter pylori

Contact Info

Product

Resources

About